101 results about "Infected cell" patented technology

The invention discloses a method for treating chicken chronic respiratory diseases by using MG-sEV-miRNA-200, and belongs to the technical field of exosomes, and the method comprises the following steps: step 1, constructing an MG infected cell model, and carrying out fluorescence quantitative analysis on gga-miR-200a-3p in cells / exosomes in different time periods of infection; step 2, carrying out overexpression on the miR-200 in the ACE II cells, and extracting an exosome (MG-sEV-miRNA-200) rich in the miR-200; step 3, constructing a cell model for exosome treatment, and carrying out RNA-seq sequencing to identify an exosome treatment target and a pathway rich in gga-miR-200a-3p; step 4, constructing a chick embryo model infected by MG, and injecting MG-sEV-miRNA-200 to intervene in respiratory diseases caused by MG; 5, evaluating the curative effect; mG-sEV is taken as a medium, miRNA can be protected from being influenced by RNA enzyme activity, the gga-miR-200a-3p-rich MG-sEV has the advantages of low immunogenicity, low cytotoxicity, relatively high stability, relatively high biocompatibility and the like, and the MG-sEV rich in gga-miR-200a-3p can be used for remarkably relieving lung inflammation injury caused by MG infection and reducing the bacterium carrying amount of MG in lung tissues; the method has a wide application prospect in the treatment of chicken chronic respiratory diseases.

Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a cancer cell, a virus-infected cell, or a fibrotic cell.

The invention belongs to the field of biology, and relates to a broad-spectrum monoclonal antibody aiming at avian influenza virus M1 protein and application of the broad-spectrum monoclonal antibody, the monoclonal antibody has specific reaction with A549 cells infected by avian influenza, has no specific reaction with Newcastle disease virus, duck tembusu virus, goose astrovirus and infectious laryngitis virus, has good specificity, and can be used for preparing the broad-spectrum monoclonal antibody. The 5G9 monoclonal antibody has good reactivity with A549 cells infected by H1-H11 subtype AIV, has good broad spectrum, can be used for detecting M1 protein sub-localization after the AIV infected cells are detected by using the 5G9 monoclonal antibody, and can be used for indicating the infection process of the AIV.

The invention provides a method of preparing a vaccine composition. The method includes infecting gene-edited porcine endogenous retrovirus (PERV) negative swine cells with a microorganism which expresses at least one protein antigen capable of inducing protective immunity in an animal against an infectious agent; culturing the infected cells in culture medium to propagate the microorganism; and harvesting the propagated microorganism from the culture medium to obtain a fraction comprising a PERV free antigen for use in immunizing an animal against the infectious agent.

The invention provides a TCR (T cell receptor) capable of being specifically combined with an HPV-16E7 protein 11-19 amino acid (sequence: YMLDLQPET) peptide fragment. The peptide fragment and HLA-A * 02 can form a compound to exist on the surface of an HPV-16 infected cell. The invention also provides a nucleic acid molecule for coding the TCR and a carrier containing the nucleic acid molecule. In addition, the invention also provides a cell for transducing the TCR.

The invention provides a method of preparing a vaccine composition. The method includes infecting gene-edited porcine endogenous retrovirus (PERV) negative swine cells with a microorganism which expresses at least one protein antigen capable of inducing protective immunity in an animal against an infectious agent; culturing the infected cells in culture medium to propagate the microorganism; and harvesting the propagated microorganism from the culture medium to obtain a fraction comprising a PERV free antigen for use in immunizing an animal against the infectious agent.

The invention relates generally to replication defective HSV-1 vectors, and, more particularly, the invention relates to replication defective HSV-1 vectors comprising an alteration (such as a gene deletion) that prevents expression of one or more infected cell polypeptide 4 (ICP4) and infected cell polypeptide 47 (ICP47) proteins, and their use to deliver one or more genes encoding transgenic proteins that stimulate immune destruction of tumors.

Chemical agents are added to standard production methods for recombinant adeno-associated viral vector to alter intracellular trafficking pathways in producer cells. This achieves, per producer cell, the synthesis of more genome containing vector particles and particles that are better transducing agents. Vector so produced also has: a greater propensity for export out of the producer cell, a more gradual transduction of infected cells, an enhanced ability for integration into the genome of cells that are coinfected by the adeno-associated virus, and an increased probability of transforming cells with multiple vectors.

This invention provides a vaccinia virus that induces cell fusion between infected cells and a method for producing the same. Such vaccinia virus is deprived of the K2L gene or the HA gene or functions of the K2L gene and the HA gene and is mutated to induce cell fusion between infected cells and induce cell death.

A protein recovery determination system includes: a first determination unit that inputs first image data obtained by imaging a culture of a virus-infected cell population in time series as first input data, and determines, as first output data, whether the virus-infected cell population is in a state suitable for protein recovery; and an acquisition unit that acquires image data by capturing an image of the inside of the culture vessel in time series, the first determination unit performs determination using a first model in which the actual performance value of the first input data and the actual performance value of the first output data are used as first training data, and the first training data are used as second training data. And deeply learning the first neural network to obtain a learned model.

Described herein are compositions and methods for reducing or eliminating latent herpes simplex virus type 2 (HSV-2) in HSV-2 infected cells, or for reducing or eliminating latent HSV-2 reactivation in HSV-2 infected cells, thereby providing viable therapeutic methods for latent HSV-2 infection. The compositions comprise a plurality of viral vectors, where the viral vectors comprise a sequence encoding a HSV-2 specific megasuclease. The method comprises delivering a plurality of one or more viral vectors to the HSV-2 infected cell, where each of the one or more viral vectors comprises a sequence encoding an HSV-2 specific megasuclease.

The invention discloses application of RMTE in preparation of a medicine for preventing and controlling grass carp reovirus. The hemorrhagic disease caused by the grass carp reovirus (GCRV) is a key bottleneck restricting healthy development of the grass carp breeding industry, and the current vaccine for treating the grass carp reovirus (GCRV) has the problems of unstable immune protection effect, low protection rate for crossing of strains of different genotypes and the like, so that the research and development process of antiviral drugs is slow. The invention discloses an influence and a potential mechanism of a rhodamine B-ethyl sulfide condensation compound (RMTE) on GCRV (Growth Factor Receptor Virus) infection. Results show that the RMTE can significantly inhibit expression of VP6 and VP7 genes in GCRV infected cells, can effectively relieve expression inhibition of GCRV on GPX4, Caspase and p53 genes and promote expression of the three genes, and prove that the RMTE has a significant inhibition effect on GCRV infection and plays an antiviral effect through multiple ways. Research results provide new potential drugs and theoretical basis for prevention and control of GCRV.

Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a cancer cell, a virus-infected cell, or a fibrotic cell.

The invention relates to an infectious arenavirus particle that is genetically engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but incapable of producing further infectious progeny particles in normal, non-genetically engineered cells.One or more of the four arenavirus open reading frames glycoprotein (GP), nucleoprotein (NP), matrix protein Z, and RNA-dependent RNA polymerase L are removed or mutated to prevent replication in normal cells, but still allow gene expression in arenavirus vector-infected cells, and foreign genes encoding an antigen or other protein of interest or nucleic acids that regulate host gene expression are expressed under the control of arenavirus promoters, internal ribosome entry sites, or under the control of regulatory elements that can be read by the viral RNA-dependent RNA polymerase, cellular RNA polymerase I, RNA polymerase II, or RNA polymerase III. The modified arenaviruses are useful as vaccines and therapeutic agents for a variety of diseases.

The present invention provides a method for efficiently delivering a transgene to the brain of a subject. The method includes intrathecal administration or one or more injections into the striatum of a replication defective herpes simplex virus (rdHSV) vector comprising an inactivating mutation of one copy of infected cell protein 0 (ICP0) HSV gene; and wherein the rdHSV-1 vector expresses a functional ICP0 protein from the other copy of the ICP0 gene.

The invention discloses an application of a small molecule compound in inhibiting HBV (Hepatitis B Virus) replication and treating hepatitis B. According to the application of the small molecule compound C18H12F3N3OS in resisting hepatitis B virus (HBV) provided by the invention, systematic in-vitro and in-vivo experiments prove that the compound can effectively inhibit the replication and expression of the HBV through a multi-target action mechanism. Experimental data show that the compound can significantly reduce the total virus RNAs level in HBV infected cells and the expression level of HBVpgRNA and HBc proteins under the micromolar concentration, and can reduce the expression of HBeAg in a dose-dependent manner. The small molecule compound has the advantages of good chemical structure solubility and low toxicity (CC50gt; and the compound is expected to be applied to clinical transformation of anti-HBV drugs.

Provided herein are methods for ex vivo expansion of a specialized subset of natural killer (NK) cells, and compositions containing such NK cells. Also provided are methods for identifying or detecting a specialized subset of NK cells. Also provided are methods for treating diseases and conditions such as cancer using provided compositions, including in combination with an antibody capable of binding to disease-associated tissues or cells, such as tumor cells or infected cells.

Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRPα on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.

Formulations and uses thereof are provided for supporting human natural defense against viral infections as well as providing treatment for viral infections susceptible to a lysosomotropic agent. Administration of a lysosomotropic agent, such as ammonium chloride (NH4Q), can militate against the uncoating of viruses within the lysosome of an infected cell and thereby minimize infection by viruses whose replication cycle relies upon an uncoating step in such a manner.

The invention relates to the technical field of traditional Chinese medicine extract fermentation, and provides a microspore ganoderma lucidum immune protein and herba houttuyniae fermentation method for treating AIDS and application of microspore ganoderma lucidum immune protein and herba houttuyniae fermentation method.The microspore ganoderma lucidum immune protein and herba houttuyniae fermentation method comprises the steps that microspore ganoderma lucidum strains and herba houttuyniae fermentation liquor are co-fermented, beta-cyclodextrin-selenocystine of a specially-made additive is combined, and the microspore ganoderma lucidum immune protein is obtained; the problems that in traditional AIDS treatment, latent infection cells are difficult to remove, toxic and side effects of drugs are remarkable, and the reconstruction efficiency of an immune system is low are effectively solved, experiments prove that the fermentation product can activate the immune system, the cell number and the dendritic cell maturity are remarkably improved, and the curative effect is good. Meanwhile, the multi-target antiviral effect is achieved by blocking virus envelope combination, inhibiting reverse transcriptase activity and inducing latent infection cell apoptosis; the anti-oxidation and anti-inflammatory characteristics can reduce the risk of opportunistic infection, reduce the toxic damage of antiviral drugs to liver, kidney and intestinal tracts, and provide a new scheme for comprehensive treatment of AIDS and nutrition support of patients.

Formulations and uses thereof are provided for supporting human natural defense against viral infections as well as providing treatment for viral infections susceptible to a lysosomotropic agent. Administration of a lysosomotropic agent, such as ammonium chloride (NH4Cl), can militate against the uncoating of viruses within the lysosome of an infected cell and thereby minimize infection by viruses whose replication cycle relies upon an uncoating step in such a manner.

This invention provides compositions and methods to prevent aberrant cell proliferation in a subject using a single-domain antibody (sdAb) directed against an intracellular component, wherein the aberrant cell proliferation can be cancer. The sdAb is synergistic with one or more chemotherapeutic drugs and improves therapeutic efficacy of the one or more chemotherapeutic drug against cancer. The invention also includes a method of treating viral infections using a sdAb, wherein the sbAb inhibits the replication of viruses such as Ebola virus and Zika virus in infected cells.